MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Witvrouw, M.
Right arrow Articles by Pannecouque, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Witvrouw, M.
Right arrow Articles by Pannecouque, C.

Vol. 58, Issue 5, 1100-1108, November 2000

Polyanionic (i.e., Polysulfonate) Dendrimers Can Inhibit the Replication of Human Immunodeficiency Virus by Interfering with Both Virus Adsorption and Later Steps (Reverse Transcriptase/Integrase) in the Virus Replicative Cycle

Myriam Witvrouw, Valery Fikkert, Wim Pluymers, Barry Matthews, Karen Mardel, Dominique Schols, John Raff, Zeger Debyser, Erik De Clercq, George Holan, and Christophe Pannecouque

Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium (M.W., V.F., W.P., D.S., Z.D., E.D.C., C.P.); Biomolecular Research Institute, Clayton, Victoria, Australia (B.M., G.H.); and Starpharma, Ltd., Clayton, Victoria, Australia (K.M., J.R.)

Polyanionic dendrimers were synthesized and evaluated for their antiviral effects. Phenyldicarboxylic acid (BRI6195) and naphthyldisulfonic acid (BRI2923) dendrimers were found to inhibit the replication of human immunodeficiency virus type 1 (HIV-1; strain IIIB) in MT-4 cells at a EC50 of 0.1 and 0.3 µg/ml, respectively. The dendrimers were not toxic to MT-4 cells up to the highest concentrations tested (250 µg/ml). These compounds were also effective against various other HIV-1 strains, including clinical isolates, HIV-2 strains, simian immunodeficiency virus (SIV, strain MAC251), and HIV-1 strains that were resistant to reverse transcriptase inhibitors. HIV strains containing mutations in the envelope glycoprotein gp120 (engendering resistance to known adsorption inhibitors) displayed reduced sensitivity to the dendrimers. The compounds inhibited the binding of wild-type virus and recombinant virus (containing wild-type gp120) to MT-4 cells at concentrations comparable to those that inhibited the replication of HIV-1(IIIB) in these cells. Cellular uptake studies indicated that BRI2923, but not BRI6195, permeates into MT-4 and CEM cells. Accordingly, the naphtyldisulfonic acid dendrimer (BRI2923) proved able to inhibit later steps of the replication cycle of HIV, i.e., reverse transcriptase and integrase. NL4.3 strains resistant to BRI2923 were selected after passage of the virus in the presence of increasing concentrations of BRI2923. The virus mutants showed 15-fold reduced sensitivity to BRI2923 and cross-resistance to known adsorption inhibitors. However, these virus mutants were not cross-resistant to reverse transcriptase inhibitors or protease inhibitors. We identified several mutations in the envelope glycoprotein gp120 gene (i.e., V2, V3, and C3, V4, and C4 regions) of the BRI2923-resistant NL4.3 strains that were not present in the wild-type NL4.3 strain, whereas no mutations were found in the reverse transcriptase or integrase genes.

Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
S. Roth, M. Monsour, A. Dowland, P. C. Guenthner, K. Hancock, C.-Y. Ou, and C. S. Dezzutti
Effect of Topical Microbicides on Infectious Human Immunodeficiency Virus Type 1 Binding to Epithelial Cells
Antimicrob. Agents Chemother., June 1, 2007; 51(6): 1972 - 1978.
[Abstract] [Full Text] [PDF]

Home page
 ADRHome page
N.M. Moutsopoulos, T. Greenwell-Wild, and S.M. Wahl
Differential Mucosal Susceptibility in HIV-1 Transmission and Infection
Advances in Dental Research, April 1, 2006; 19(1): 52 - 56.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
M. Witvrouw, V. Fikkert, A. Hantson, C. Pannecouque, B. R. O'Keefe, J. McMahon, L. Stamatatos, E. de Clercq, and A. Bolmstedt
Resistance of Human Immunodeficiency Virus Type 1 to the High-Mannose Binding Agents Cyanovirin N and Concanavalin A
J. Virol., June 15, 2005; 79(12): 7777 - 7784.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
C. S. Dezzutti, V. N. James, A. Ramos, S. T. Sullivan, A. Siddig, T. J. Bush, L. A. Grohskopf, L. Paxton, S. Subbarao, and C. E. Hart
In Vitro Comparison of Topical Microbicides for Prevention of Human Immunodeficiency Virus Type 1 Transmission
Antimicrob. Agents Chemother., October 1, 2004; 48(10): 3834 - 3844.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
J. Rojo and R. Delgado
Glycodendritic structures: promising new antiviral drugs
J. Antimicrob. Chemother., September 1, 2004; 54(3): 579 - 581.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
D. I. Bernstein, L. R. Stanberry, S. Sacks, N. K. Ayisi, Y. H. Gong, J. Ireland, R. J. Mumper, G. Holan, B. Matthews, T. McCarthy, et al.
Evaluations of Unformulated and Formulated Dendrimer-Based Microbicide Candidates in Mouse and Guinea Pig Models of Genital Herpes
Antimicrob. Agents Chemother., December 1, 2003; 47(12): 3784 - 3788.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
V. Fikkert, P. Cherepanov, K. Van Laethem, A. Hantson, B. Van Remoortel, C. Pannecouque, E. De Clercq, Z. Debyser, A.-M. Vandamme, and M. Witvrouw
env Chimeric Virus Technology for Evaluating Human Immunodeficiency Virus Susceptibility to Entry Inhibitors
Antimicrob. Agents Chemother., December 1, 2002; 46(12): 3954 - 3962.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
E. De Clercq
Molecular Targets for Antiviral Agents
J. Pharmacol. Exp. Ther., April 1, 2001; 297(1): 1 - 10.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics